The Hidden Layer of PBMs: What a Recent Investigation Reveals

Why It Matters

The concealed GPO network amplifies cost opacity, inflating drug prices for employers, insurers, and patients, and threatens effective policy interventions aimed at improving affordability.

Key Takeaways

• PBM GPOs funnel billions while operating with minimal staff
• Big three PBMs control 80% of U.S. prescriptions
• Overseas GPOs add opacity to PBM pricing structures
• Congressional reform introduced, but deeper transparency needed
• Complex GPO design intentionally hides fees from plan sponsors

Pulse Analysis

Pharmacy benefit managers have long been the invisible middlemen shaping drug pricing, but the latest Hunterbrook investigation reveals an even deeper layer of opacity: PBM‑affiliated group purchasing organizations. These GPOs, some registered abroad, act as financial conduits that aggregate purchasing power on paper while diverting substantial revenue streams away from plan sponsors. By maintaining skeletal staff and limited public footprints, they evade traditional oversight mechanisms, allowing PBMs to retain a larger share of the savings that should flow to patients at the pharmacy counter.

The concentration of power in the PBM market intensifies the impact of these hidden entities. With the three dominant PBMs overseeing roughly 80% of all prescriptions, their vertical integration with major insurers creates a closed ecosystem where pricing decisions are rarely transparent. The overseas GPOs exacerbate this secrecy, making it nearly impossible for employers, unions, Medicaid programs, and commercial insurers to verify whether they receive the best possible rates. Analysts argue that the complexity is not accidental; it is a strategic design to shield fee structures from scrutiny, effectively inflating drug costs across the healthcare system.

Legislative bodies have begun to respond, with recent bipartisan measures marking the first step toward PBM reform. However, the investigation underscores that superficial changes will not suffice. Effective policy must target the GPO layer, mandating disclosure of fee arrangements, enforcing antitrust safeguards, and requiring independent audits of PBM‑GPO financial flows. Such actions would restore market transparency, reduce unnecessary cost burdens, and align drug pricing more closely with the goal of broader patient access.